A Safety Study of Contralateral Eye Dosing of VGR-R01 in Participants With Bietti's Crystalline Dystrophy (BCD)
A Clinical Study Evaluating Subretinal Injection of VGR-R01 in the Contralateral Eye of Participants With Bietti's Crystalline Dystrophy Who Had Received VGR-R01 Administration
Studie Overzicht
Toestand
Toestand
Conditie
Conditie
Interventie / Behandeling
Interventie / Behandeling
Gedetailleerde beschrijving
Studietype
Studietype
Inschrijving (Geschat)
Inschrijving
Fase
Fase
- Fase 2
- Fase 1
Contacten en locaties
Studiecontact
Studiecontact
- Naam: Yan Jiang
- Telefoonnummer: 086-15802234907
- E-mail: yan.jiang@vitalgen.com
Studie Locaties
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China
- Beijing Tongren Hospital
-
Contact:
- Yan Jiang
- Telefoonnummer: 086-15802234907
- E-mail: yan.jiang@vitalgen.com
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, China
- Shanghai General Hospital (Shanghai First People's Hospital)
-
Contact:
- Yan Jiang
- Telefoonnummer: 086-15802234907
- E-mail: yan.jiang@vitalgen.com
-
-
Deelname Criteria
Geschiktheidscriteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Beschrijving
Key Inclusion Criteria:
- Participants received VGR-R01 administration in the VGR-R01-001 or VGR-R01-101 studies.
- Able to provide informed consent and comply with requirements of the study;
- Hand Motion ≤ BCVA ≤ 75 ETDRS letters in the second treated eye.
Key Exclusion Criteria:
- Have insufficient viable retinal photoreceptor cells based on investigator's decision;
- Have current ocular or periocular infections, or endophthalmitis;
- Have any significant ocular disease/disorder other than BCD, including age-related macular degeneration, diabetic retinopathy, optic neuropathy, significant lens opacity, glaucoma, uveitis, retinal detachment, etc;
- Have intraocular surgery history except cataract surgery in the study eye;
- Have or potentially require of systemic medications that may cause eye injure;
- Have contraindications for corticosteroids or immunosuppressant;
- Abnormal coagulation function or other clinically significant abnormal laboratory results;
- Have malignancies or history of malignancies;
- History of immunodeficiency (acquired or congenital); Other protocol defined Inclusion/Exclusion criteria may apply.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Aantal wapens
Wapens en interventies
Deelnemersgroep / ArmDeelnemersgroep / Arm |
Interventie / BehandelingInterventie / Behandeling |
|---|---|
|
Experimenteel: VGR-R01 group
Single-dose Subretinal Administration of VGR-R01
|
CYP4v2-coding gene delivered by AAV vector
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Incidence of adverse events and serious adverse events
Tijdsspanne: Up to Year 5
|
Ocular/non-ocular adverse events are collected.
The ophthalmic examination will include Best Corrected Visual Acuity (BCVA), Intraocular Pressure (IOP), slit lamp examination, angiography and Optical Coherence Tomography (OCT), etc.
If any potential changes accompanied by clinical symptoms, or results in a change of medical intervention, the findings will be considered as clinically significant based on investigator's decision.
|
Up to Year 5
|
|
Number of participants with clinically significant change from baseline in vital signs, clinically laboratory abnormalities and ophthalmic examination findings
Tijdsspanne: Up to Year 5
|
Vital signs (temperature, respiratory rate, pulse rate, systolic and diastolic blood pressure) will be obtained with participant in the seated position, after having sat calmly for at least 10 minutes.
Laboratory Tests will include hematology, coagulation, blood chemistry, urinalysis, serology, and pregnancy test, etc. Ophthalmic Examination will include BCVA, IOP, slit lamp examination, angiography and OCT, etc. Clinical significance of the above signs will be determined at the investigator's discretion.
|
Up to Year 5
|
Secundaire uitkomstmaten
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change from baseline in BCVA
Tijdsspanne: Year 5
|
BCVA will be assessed with the Early Treatment of Diabetic Retinopathy Study (ETDRS) visual acuity (VA) chart..
|
Year 5
|
|
Change from baseline in multi-luminance mobility test (MLMT) score
Tijdsspanne: Year 5
|
Subjects will navigate a standardized mobility maze under set conditions as specified times during the study.
All light-levels used for testing will be rounded to one of the following specified light levels: 0.1, 1, 4, 10, 50, 125, 250, or 400 lux.
The corresponding scores for the above light levels range from 7 to 0, in descending order.
-1 point means failing to pass the test at the 400 lux level; the lower the score, the worse the functional vision of the participant.
|
Year 5
|
|
Change from baseline in optical coherence tomography (OCT)
Tijdsspanne: Year 5
|
Change from baseline in central retinal thickness (CRT) as imaged by OCT.
|
Year 5
|
|
Number of subjects with the presence of immunogenicity
Tijdsspanne: Year 5
|
Assessed as presence of systemic cell-mediated or humoral responses to capsid or transgene product.
|
Year 5
|
|
Number of subjects with the presence of vector shedding
Tijdsspanne: Year 5
|
Assessed as the presence of vector in peripheral blood or collected tear.
|
Year 5
|
|
Fixation stability
Tijdsspanne: Year 5
|
Number of treated eyes with changes from baseline in fixation stability with MP-3 Microperimetry.
Fixation stability is rated into three levels: stable fixation, relatively unstable fixation, and unstable fixation, with fixed standard reporting on the device settings.
|
Year 5
|
|
Light sensitivity
Tijdsspanne: Year 5
|
Changes from baseline in light sensitivity with MP-3 Microperimetry.
The MP-3 has a stimulus intensity range of 0 to 34 decibels (dB).
|
Year 5
|
Andere uitkomstmaten
Andere uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Visual field index (VFI)
Tijdsspanne: Year 5
|
Assessed by Humphery static visual field testing.
The VFI is a sophisticated index that range from 0% to 100%.
It estimates the percentage of the visual field that the higher the better of visual function.
Changes from baseline in VFI will be evaluated.
|
Year 5
|
|
Central threshold test
Tijdsspanne: Year 5
|
The central threshold test is a parameter in the Humphrey visual field test report, used to quantitatively assess the light sensitivity of the fovea (the area that provides the clearest central vision).
It is a numerical value expressed in decibels (dB); the higher the value, the better the foveal light sensitivity.
|
Year 5
|
|
Change from baseline in NEI-VFQ-25 score
Tijdsspanne: Year 5
|
As assessed by the National Eye Institute Visual Function Questionnaire -25 (NEI-VFQ-25 questionnaire).
NEI-VFQ-25 score ranges from 0 to 100, higher scores indicate better quality of life.
|
Year 5
|
|
Change from baseline in CLVQOL score
Tijdsspanne: Year 5
|
As assessed by the Chinese version of the Low Vision Quality-of-Life Questionnaire (CLVQOL questionnaire).
CLVQOL score ranges from 0 to 125; higher scores indicate better quality of life.
|
Year 5
|
Medewerkers en onderzoekers
Sponsor
Sponsor
Onderzoekers
Onderzoekers
- Hoofdonderzoeker: Wenbin Wei, Beijing Tongren Hospital
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Studie start
Primaire voltooiing (Geschat)
Primaire voltooiing
Studie voltooiing (Geschat)
Studie voltooiing
Studieregistratiedata
Eerst ingediend
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Eerst geplaatst
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update geplaatst
Laatste update ingediend die voldeed aan QC-criteria
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
Andere studie-ID-nummers
- VGR-R01-102
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .